Nasdaq · CIK 0001347178
VNDA Vanda Pharmaceuticals Inc.
Insider trading from SEC Form 4. Last filing Jun 8, 2026. Close $4.57 on Oct 9, 2026, +6% from the 52-week low and -52% from the high.
Vanda Pharmaceuticals Inc. (VNDA) has 28 SEC Form 4 filings on file from 11 insiders, the latest filed on Jun 8, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
11 open-market trades have been scored at VNDA. The newest: Gunther Birznieks (SVP, Business Development) sold $351k of stock on Mar 2, 2026, filed Mar 4, 2026, scored 45 (moderate). The largest of the 11 shown: Mihael Hristos Polymeropoulos (President and CEO) sold $1.3M on Mar 2, 2026, scored 65 (notable). 6 insiders sold within 14 days of each other around Mar 2, 2026.
VNDA closed at $4.57 on Oct 9, 2026, 6% above its 52-week low and 52% below its 52-week high.
2 Form 144 notices of planned sales are on file, the latest filed Jun 13, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Vanda Pharmaceuticals Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Gunther Birznieks SVP, Business Development sell | $351k 42,431 shares | -8% | +108% from low-8% from high | |
| 52Moderate | Kevin Patrick Moran SVP, CFO & Treasurer sell | $351k 42,442 shares | -9% | +108% from low-8% from high | |
| 65Notable | Mihael Hristos Polymeropoulos President and CEO sell | $1.3M 156,235 shares | -5% | +108% from low-8% from high | |
| 50Moderate | Timothy Williams SVP & General Counsel sell | $351k 42,434 shares | -10% | +108% from low-8% from high | |
| 43Moderate | Joakim Wijkstrom SVP, Chief Marketing Officer sell | $255k 30,800 shares | -8% | +108% from low-8% from high | |
| 48Moderate | Tage Honore director sell | $241k 30,000 shares | -24% | +108% from low-8% from high | |
| 45Moderate | Mihael Hristos Polymeropoulos President and CEO buy | $42k 10,000 shares | +0% | +7% from low-23% from high | |
| 20Weak | Stephen Ray Mitchell director sell | $32k 7,000 shares | -7% | +15% from low-17% from high | |
| 35Weak | Mihael Hristos Polymeropoulos President and CEO buy | $44k 10,000 shares | +0% | +10% from low-21% from high | |
| 43Moderate | Mihael Hristos Polymeropoulos President and CEO buy | $84k 20,000 shares | +1% | +6% from low-24% from high | |
| 25Weak | Stephen Ray Mitchell director sell | $26k 5,000 shares | -10% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 13, 2025 | Mitchell Stephen Ray Director | 7,000 0.01% of outstanding | $32k | Jun 13, 2025 | none |
| Nov 14, 2024 | Mitchell Stephen Ray Director | 5,000 0.01% of outstanding | $27k | Nov 14, 2024 | none |
Transactions
Every row filed, 29 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Richard W Dugan director | AGrant or award Common Stock | +41,600 | $0.00 | $0 | 219,054 | Jun 8, 2026 |
| Jun 4, 2026 | Charles Cliff Duncan director | AGrant or award Common Stock | +41,600 | $0.00 | $0 | 98,701 | Jun 8, 2026 |
| Jun 4, 2026 | Tage Honore director | AGrant or award Common Stock | +41,600 | $0.00 | $0 | 135,069 | Jun 8, 2026 |
| Jun 4, 2026 | Phaedra Chrousos director | AGrant or award Common Stock | +41,600 | $0.00 | $0 | 164,950 | Jun 8, 2026 |
| Apr 22, 2026 | Charles Cliff Duncan director | AGrant or award Common Stock | +57,101 | $0.00 | $0 | 57,101 | Apr 24, 2026 |
| Mar 2, 2026 | Gunther Birznieks SVP, Business Development | SOpen-market sale Common Stock | -42,431 | $8.27 | $351k | 494,197 | Mar 4, 2026 |
| Mar 2, 2026 | Kevin Patrick Moran SVP, CFO & Treasurer | SOpen-market sale Common Stock | -42,442 | $8.27 | $351k | 411,380 | Mar 4, 2026 |
| Mar 2, 2026 | Mihael Hristos Polymeropoulos President and CEO | SOpen-market sale Common Stock | -156,235 | $8.17 | $1.3M | 2,704,496 | Mar 4, 2026 |
| Mar 2, 2026 | Timothy Williams SVP & General Counsel | SOpen-market sale Common Stock | -42,434 | $8.27 | $351k | 377,450 | Mar 4, 2026 |
| Mar 2, 2026 | Joakim Wijkstrom SVP, Chief Marketing Officer | SOpen-market sale Common Stock | -30,800 | $8.27 | $255k | 333,469 | Mar 4, 2026 |
| Feb 23, 2026 | Tage Honore director | SOpen-market sale Common Stock | -30,000 | $8.03 | $241k | 93,469 | Feb 24, 2026 |
| Feb 18, 2026 | Timothy Williams SVP & General Counsel | AGrant or award Common Stock | +125,000 | $0.00 | $0 | 419,884 | Feb 19, 2026 |
| Feb 18, 2026 | Joakim Wijkstrom SVP, Chief Marketing Officer | AGrant or award Common Stock | +125,000 | $0.00 | $0 | 364,269 | Feb 19, 2026 |
| Feb 18, 2026 | Mihael Hristos Polymeropoulos President and CEO | AGrant or award Common Stock | +525,000 | $0.00 | $0 | 2,860,731 | Feb 19, 2026 |
| Feb 18, 2026 | Kevin Patrick Moran SVP, CFO & Treasurer | AGrant or award Common Stock | +125,000 | $0.00 | $0 | 453,822 | Feb 19, 2026 |
| Feb 18, 2026 | Gunther Birznieks SVP, Business Development | AGrant or award Common Stock | +125,000 | $0.00 | $0 | 536,628 | Feb 19, 2026 |
| Aug 7, 2025 | Mihael Hristos Polymeropoulos President and CEO | POpen-market purchase Common Stock | +10,000 | $4.15 | $42k | 2,335,731 | Aug 8, 2025 |
| Jun 13, 2025 | Stephen Ray Mitchell director | SOpen-market sale Common Stock | -7,000 | $4.59 | $32k | 97,082 | Jun 16, 2025 |
| Jun 5, 2025 | Phaedra Chrousos director | AGrant or award Common Stock | +59,225 | $0.00 | $0 | 123,350 | Jun 9, 2025 |
| Jun 5, 2025 | Richard W Dugan director | AGrant or award Common Stock | +59,225 | $0.00 | $0 | 177,454 | Jun 9, 2025 |
| Jun 5, 2025 | Tage Honore director | AGrant or award Common Stock | +59,225 | $0.00 | $0 | 123,469 | Jun 9, 2025 |
| Jun 5, 2025 | Stephen Ray Mitchell director | AGrant or award Common Stock | +59,225 | $0.00 | $0 | 104,082 | Jun 9, 2025 |
| Jun 5, 2025 | Anne Sempowski Ward director | AGrant or award Common Stock | +59,225 | $0.00 | $0 | 119,067 | Jun 9, 2025 |
| May 21, 2025 | Mihael Hristos Polymeropoulos President and CEO | POpen-market purchase Common Stock | +9,519 | $4.40 | $42k | 2,325,250 | May 21, 2025 |
| May 21, 2025 | Mihael Hristos Polymeropoulos President and CEO | POpen-market purchase Common Stock | +481 | $4.39 | $2,112 | 2,325,731 | May 21, 2025 |
| May 16, 2025 | Mihael Hristos Polymeropoulos President and CEO | POpen-market purchase Common Stock | +20,000 | $4.22 | $84k | 2,315,731 | May 19, 2025 |
| Mar 1, 2025 | Gunther Birznieks SVP, Business Development | FTax withholding Common Stock | -26,941 | $4.76 | $128k | 411,628 | Mar 4, 2025 |
| Feb 18, 2025 | Gunther Birznieks SVP, Business Development | AGrant or award Common Stock | +125,000 | $0.00 | $0 | 438,569 | Feb 20, 2025 |
| Nov 14, 2024 | Stephen Ray Mitchell director | SOpen-market sale Common Stock | -5,000 | $5.17 | $26k | 44,857 | Nov 18, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Gunther BirznieksSVP, Business Development
- Phaedra Chrousosdirector
- Richard W Dugandirector
- Charles Cliff Duncandirector
- Tage Honoredirector
- Stephen Ray Mitchelldirector
- Kevin Patrick MoranSVP, CFO & Treasurer
- Mihael Hristos PolymeropoulosPresident and CEO
- Anne Sempowski Warddirector
- Joakim WijkstromSVP, Chief Marketing Officer
- Timothy WilliamsSVP & General Counsel
Questions about VNDA
Answered from the filings on this page, as of the latest one.
Are insiders buying VNDA?
No. In the last 90 days no insider at Vanda Pharmaceuticals Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade VNDA on the open market?
Gunther Birznieks (SVP, Business Development) sold $351k of VNDA on Mar 2, 2026 and filed the Form 4 on Mar 4, 2026. InsiderTell scored 45 (moderate), with 6 insiders on the same side within 14 days.
How many insiders file Form 4 at Vanda Pharmaceuticals Inc.?
11 people have filed a Form 4 at Vanda Pharmaceuticals Inc., among them Gunther Birznieks (SVP, Business Development), Phaedra Chrousos (director), Richard W Dugan (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.